{"title":"Capivasertib治疗与脾高代谢相关。","authors":"Maria Ly, Gary Z Yu, Amin Haghighat Jahromi","doi":"10.1186/s41824-024-00231-7","DOIUrl":null,"url":null,"abstract":"<p><p>Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"9 1","pages":"10"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930895/pdf/","citationCount":"0","resultStr":"{\"title\":\"Capivasertib treatment associated with hypermetabolism of the spleen.\",\"authors\":\"Maria Ly, Gary Z Yu, Amin Haghighat Jahromi\",\"doi\":\"10.1186/s41824-024-00231-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.</p>\",\"PeriodicalId\":519909,\"journal\":{\"name\":\"EJNMMI reports\",\"volume\":\"9 1\",\"pages\":\"10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930895/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41824-024-00231-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41824-024-00231-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Capivasertib treatment associated with hypermetabolism of the spleen.
Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
